---
title: "12 Health Care Stocks Moving In Tuesday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289241208.md"
description: "In Tuesday's after-market session, several healthcare stocks moved significantly. Gainers included Cellectis (+17.1%), Context Therapeutics (+8.55%), and Curanex Pharmaceuticals (+7.1%). Conversely, losers featured Picard Medical (-16.6%), Scinai Immunotherapeutics (-15.33%), and VolitionRX (-8.83%). The report highlights specific price changes and market capitalizations for these companies during the extended trading hours."
datetime: "2026-06-09T21:06:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289241208.md)
  - [en](https://longbridge.com/en/news/289241208.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289241208.md)
---

# 12 Health Care Stocks Moving In Tuesday's After-Market Session

### Gainers

-   **Cellectis** (NASDAQ:CLLS) stock increased by 17.1% to $3.5 during Tuesday's after-market session. The company's market cap stands at $294.7 million.
-   **Context Therapeutics** (NASDAQ:CNTX) shares moved upwards by 8.55% to $1.65. The company's market cap stands at $157.1 million.
-   **Curanex Pharmaceuticals** (NASDAQ:CURX) shares rose 7.1% to $0.33. The company's market cap stands at $8.6 million.
-   **Pomdoctor** (NASDAQ:POM) stock increased by 6.74% to $0.12. The company's market cap stands at $13.3 million.
-   **60 Degrees** (NASDAQ:SXTP) shares increased by 6.47% to $1.48. The market value of their outstanding shares is at $3.8 million.
-   **Genenta Science** (NASDAQ:GNTA) shares increased by 6.24% to $1.7. The company's market cap stands at $42.1 million.

### Losers

-   **Picard Medical** (AMEX:PMI) shares fell 16.6% to $0.27 during Tuesday's after-market session. The market value of their outstanding shares is at $24.6 million.
-   **Scinai Immunotherapeutics** (NASDAQ:SCNI) stock declined by 15.33% to $0.3. The market value of their outstanding shares is at $1.6 million.
-   **VolitionRX** (AMEX:VNRX) shares decreased by 8.83% to $1.24. The market value of their outstanding shares is at $11.5 million.
-   **Summit Therapeutics** (NASDAQ:SMMT) stock decreased by 8.68% to $13.05. The market value of their outstanding shares is at $10.9 billion.
-   **Universe Pharmaceuticals** (NASDAQ:UPC) stock decreased by 8.61% to $3.08. The company's market cap stands at $2.0 million.
-   **Actuate Therapeutics** (NASDAQ:ACTU) shares declined by 7.97% to $1.85. The market value of their outstanding shares is at $43.5 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)
- [PMI.US](https://longbridge.com/en/quote/PMI.US.md)
- [VNRX.US](https://longbridge.com/en/quote/VNRX.US.md)
- [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md)
- [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md)
- [CURX.US](https://longbridge.com/en/quote/CURX.US.md)
- [POM.US](https://longbridge.com/en/quote/POM.US.md)
- [SXTP.US](https://longbridge.com/en/quote/SXTP.US.md)
- [GNTA.US](https://longbridge.com/en/quote/GNTA.US.md)
- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [UPC.US](https://longbridge.com/en/quote/UPC.US.md)
- [ACTU.US](https://longbridge.com/en/quote/ACTU.US.md)
- [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md)

## Related News & Research

- [Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress | CLLS Stock News](https://longbridge.com/en/news/289421231.md)
- [As tech stocks slide, the healthcare sector shines. Why some experts say they like this defensive play](https://longbridge.com/en/news/289242691.md)
- [11:25 ETSoftware Company OnTime Announces Goal to Modernize the Home Healthcare Industry](https://longbridge.com/en/news/289211527.md)
- [A Look At Healthpeak Properties (DOC) Valuation As Recent Returns Send Mixed Signals](https://longbridge.com/en/news/289517197.md)
- [H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)](https://longbridge.com/en/news/289477645.md)